stockrowProtalix BioTherapeutics, Inc. (PLX) vs Cartesian Therapeutics, Inc. (RNAC)
- Protalix BioTherapeutics, Inc. PLX 2.54 +1.20%
- Cartesian Therapeutics, Inc. RNAC 7.53 +11.06%
Protalix BioTherapeutics, Inc. and Cartesian Therapeutics, Inc. are both Biotechnology companies. Cartesian Therapeutics, Inc. is the larger, with a market value of $229.7M against $204.7M — 1.1× the size. Cartesian Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Protalix BioTherapeutics, Inc. trades at 10.6×. Protalix BioTherapeutics, Inc. grew revenue faster over the last twelve months: 30.1% against −94.8%. Protalix BioTherapeutics, Inc. has the higher net margin (23.5% vs 0.00%) and the higher return on invested capital (48.5% vs 0.00%). Across the 17 metrics below, Protalix BioTherapeutics, Inc. leads on 11 and Cartesian Therapeutics, Inc. on 6.
Valuation
Profitability
| Metric | PLX | RNAC | Biotechnology median |
|---|---|---|---|
| Gross margin | 69.20% | 100.00% | 68.51% |
| Operating margin | 28.89% | 0.00% | 0.00% |
| Net margin | 23.50% | 0.00% | 0.00% |
| Free cash flow margin | 9.51% | 0.00% | 0.00% |
| Return on equity | 31.23% | 236.88% | (51.96%) |
| Return on assets | 20.07% | (42.77%) | (46.06%) |
| Return on invested capital | 48.48% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack